DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,779,554 | -4.4% | 15,234 | -7.5% | 0.10% | -3.7% |
| Q2 2023 | $3,954,240 | -5.7% | 16,476 | -0.9% | 0.11% | -14.3% |
| Q1 2023 | $4,192,433 | -9.1% | 16,634 | -4.3% | 0.13% | -17.6% |
| Q4 2022 | $4,612,999 | +5.0% | 17,380 | +2.2% | 0.15% | -7.8% |
| Q3 2022 | $4,392,000 | +1.0% | 17,004 | -0.9% | 0.17% | +3.8% |
| Q2 2022 | $4,348,000 | -19.9% | 17,153 | -7.3% | 0.16% | -9.1% |
| Q1 2022 | $5,427,000 | -11.8% | 18,501 | -1.1% | 0.18% | -13.7% |
| Q4 2021 | $6,155,000 | +5.2% | 18,709 | -2.7% | 0.20% | -9.7% |
| Q3 2021 | $5,853,000 | +9.0% | 19,227 | -3.9% | 0.23% | +9.2% |
| Q2 2021 | $5,371,000 | +18.8% | 20,013 | -0.3% | 0.21% | +6.2% |
| Q1 2021 | $4,520,000 | -2.9% | 20,079 | -4.1% | 0.20% | -9.7% |
| Q4 2020 | $4,653,000 | -0.4% | 20,946 | -3.5% | 0.22% | -10.7% |
| Q3 2020 | $4,672,000 | +15.4% | 21,700 | -5.2% | 0.24% | +4.8% |
| Q2 2020 | $4,049,000 | +20.7% | 22,896 | -5.5% | 0.23% | -0.9% |
| Q1 2020 | $3,354,000 | -30.5% | 24,234 | -23.0% | 0.23% | -13.7% |
| Q4 2019 | $4,828,000 | +3.1% | 31,453 | -3.0% | 0.27% | -4.6% |
| Q3 2019 | $4,684,000 | -3.0% | 32,432 | -4.0% | 0.28% | -5.7% |
| Q2 2019 | $4,827,000 | +1.1% | 33,780 | -6.6% | 0.30% | -2.0% |
| Q1 2019 | $4,776,000 | -7.2% | 36,175 | -27.5% | 0.31% | -19.5% |
| Q4 2018 | $5,145,000 | -9.3% | 49,894 | -4.4% | 0.38% | +6.1% |
| Q3 2018 | $5,672,000 | -0.5% | 52,197 | -9.7% | 0.36% | -15.6% |
| Q2 2018 | $5,703,000 | -9.3% | 57,792 | -10.0% | 0.42% | -2.3% |
| Q1 2018 | $6,290,000 | -5.6% | 64,241 | -10.5% | 0.43% | -5.4% |
| Q4 2017 | $6,661,000 | +8.2% | 71,763 | -0.0% | 0.46% | +1.8% |
| Q3 2017 | $6,157,000 | +4.7% | 71,772 | +3.0% | 0.45% | -1.1% |
| Q2 2017 | $5,878,000 | +130.3% | 69,658 | +133.5% | 0.46% | +125.7% |
| Q1 2017 | $2,552,000 | -25.9% | 29,833 | -32.6% | 0.20% | -29.1% |
| Q4 2016 | $3,444,000 | +41.0% | 44,245 | +68.3% | 0.28% | +12.2% |
| Q4 2015 | $2,442,000 | +85.3% | 26,287 | +70.9% | 0.25% | +81.4% |
| Q4 2014 | $1,318,000 | +41.7% | 15,379 | +27.6% | 0.14% | +30.8% |
| Q4 2013 | $930,000 | +56.3% | 12,052 | +13.2% | 0.11% | +21.6% |
| Q4 2012 | $595,000 | +22.7% | 10,643 | +3.2% | 0.09% | +7.3% |
| Q4 2011 | $485,000 | +34.3% | 10,312 | +34.6% | 0.08% | +32.3% |
| Q4 2010 | $361,000 | -7.4% | 7,660 | +47.9% | 0.06% | -17.3% |
| Q4 2009 | $390,000 | -31.9% | 5,180 | -48.8% | 0.08% | -45.7% |
| Q4 2008 | $573,000 | – | 10,111 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |